{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:19:20Z","timestamp":1793477960926,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T00:00:00Z","timestamp":1472774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T00:00:00Z","timestamp":1472774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There exists a great knowledge gap in terms of long-term effects of various surgical and pharmacological treatments on outcomes among primary aldosteronism (PA) patients. Using a validated algorithm, we extracted longitudinal data for all PA patients diagnosed in 1997\u20132010 and treated in the Taiwan National Health Insurance. We identified 3362 PA patients for whom the mean length of follow-up was 5.75 years. PA has higher major cardiovascular events (MACE) than essential hypertension (23.3% vs 19.3%, p\u2009=\u20090.015). Results from the Cox model suggest a strong effect of adrenalectomy on lowering mortality (HR\u2009=\u20090.23 with residual hypertension and 0.21 with resolved hypertension). While the need for mineralocorticoid receptor antagonist (MRA) after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50\u2009mg may alleviate risk of death in a U-shape pattern. A specificity test identified patients who has aldosterone producing adenoma (HR\u2009=\u20090.50, p\u2009=\u20090.005) also confirmed adrenalectomy attenuated all-cause mortality. Adrenalectomy decreases long-term all-cause mortality independently from PA cure from hypertension. Prescription corresponding to a DDD between 12.5 and 50\u2009mg may decrease mortality for patients needing MRA. It calls for more attention on early diagnosis, early treatment and prescription of appropriate dosage of MRA for PA patients.<\/jats:p>","DOI":"10.1038\/srep32103","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T09:57:00Z","timestamp":1472810220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Long term outcome of Aldosteronism after target treatments"],"prefix":"10.1038","volume":"6","author":[{"given":"Vin-Cent","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo-Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chieh Jeff","family":"Chueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likwang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan-Dun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,2]]},"reference":[{"key":"BFsrep32103_CR1","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","volume":"93","author":"JW Funder","year":"2008","unstructured":"Funder, J. W. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93, 3266\u20133281 (2008).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep32103_CR2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 45, 1243\u20131248 (2005).","journal-title":"Journal of the American College of Cardiology"},{"key":"BFsrep32103_CR3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke, M. et al. Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension 60, 618\u2013624 (2012).","journal-title":"Hypertension"},{"key":"BFsrep32103_CR4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2011.12.003","volume":"221","author":"YH Lin","year":"2012","unstructured":"Lin, Y. H. et al. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma. Atherosclerosis 221, 154\u2013159 (2012).","journal-title":"Atherosclerosis"},{"key":"BFsrep32103_CR5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","volume":"29","author":"VC Wu","year":"2011","unstructured":"Wu, V. C. et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 29, 1778\u20131786 (2011).","journal-title":"J Hypertens"},{"key":"BFsrep32103_CR6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena, C. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 168, 80\u201385 (2008).","journal-title":"Arch Intern Med"},{"key":"BFsrep32103_CR7","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/HJH.0b013e3283550f93","volume":"30","author":"YH Lin","year":"2012","unstructured":"Lin, Y. H. et al. Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism. J Hypertens 30, 1606\u20131613 (2012).","journal-title":"J Hypertens"},{"key":"BFsrep32103_CR8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1507\/endocrj.EJ13-0353","volume":"61","author":"Y Miyake","year":"2014","unstructured":"Miyake, Y. et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocrine journal 61, 35\u201340 (2014).","journal-title":"Endocrine journal"},{"key":"BFsrep32103_CR9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1055\/s-0029-1246185","volume":"42","author":"C Catena","year":"2010","unstructured":"Catena, C. et al. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 42, 440\u2013445 (2010).","journal-title":"Horm Metab Res"},{"key":"BFsrep32103_CR10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00019053-199304050-00003","volume":"4","author":"NJ Lewis","year":"1993","unstructured":"Lewis, N. J., Patwell, J. T. & Briesacher, B. A. The role of insurance claims databases in drug therapy outcomes research. PharmacoEconomics 4, 323\u2013330 (1993).","journal-title":"PharmacoEconomics"},{"key":"BFsrep32103_CR11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2215\/CJN.01240214","volume":"10","author":"PC Wu","year":"2015","unstructured":"Wu, P. C., Wu, C. J., Lin, C. J. & Wu, V. C. & National Taiwan University Study Group on Acute Renal Failure, G. Long-term risk of upper gastrointestinal hemorrhage after advanced AKI. Clin J Am Soc Nephrol 10, 353\u2013362 (2015).","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFsrep32103_CR12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.2013060610","volume":"25","author":"VC Wu","year":"2014","unstructured":"Wu, V. C. et al. Long-term risk of coronary events after AKI. J Am Soc Nephrol 25, 595\u2013605 (2014).","journal-title":"J Am Soc Nephrol"},{"key":"BFsrep32103_CR13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/jbmr.2061","volume":"29","author":"WJ Wang","year":"2013","unstructured":"Wang, W. J. et al. The impact of acute kidney injury with temporary dialysis on the risk of fracture. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 29, 676\u2013684 (2013).","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"BFsrep32103_CR14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/cpt.173","volume":"98","author":"PC Wu","year":"2015","unstructured":"Wu, P. C. et al. Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease. Clinical pharmacology and therapeutics 98, 442\u2013449 (2015).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"BFsrep32103_CR15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pds.2087","volume":"20","author":"CL Cheng","year":"2011","unstructured":"Cheng, C. L., Kao, Y. H., Lin, S. J., Lee, C. H. & Lai, M. L. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiology and drug safety 20, 236\u2013242 (2011).","journal-title":"Pharmacoepidemiology and drug safety"},{"key":"BFsrep32103_CR16","first-page":"157","volume":"104","author":"CC Lin","year":"2005","unstructured":"Lin, C. C., Lai, M. S., Syu, C. Y., Chang, S. C. & Tseng, F. Y. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi 104, 157\u2013163 (2005).","journal-title":"Journal of the Formosan Medical Association = Taiwan yi zhi"},{"key":"BFsrep32103_CR17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jclinepi.2014.05.012","volume":"67","author":"VC Wu","year":"2014","unstructured":"Wu, V. C. et al. Administrative data on diagnosis and mineralocorticoid receptor antagonist prescription identified patients with primary aldosteronism in Taiwan. Journal of clinical epidemiology 67, 1139\u20131149 (2014).","journal-title":"Journal of clinical epidemiology"},{"key":"BFsrep32103_CR18","doi-asserted-by":"crossref","first-page":"e112257","DOI":"10.1371\/journal.pone.0112257","volume":"9","author":"CS Wu","year":"2014","unstructured":"Wu, C. S., Lai, M. S., Gau, S. S., Wang, S. C. & Tsai, H. J. Concordance between Patient Self-Reports and Claims Data on Clinical Diagnoses, Medication Use, and Health System Utilization in Taiwan. PloS one 9, e112257 (2014).","journal-title":"PloS one"},{"key":"BFsrep32103_CR19","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD). Available fromhttp:\/\/www.whocc.no\/atc_ddd_index\/Accessed 18th March 2016 (2015)."},{"key":"BFsrep32103_CR20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1053\/j.ajkd.2009.06.014","volume":"54","author":"VC Wu","year":"2009","unstructured":"Wu, V. C. et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 54, 665\u2013673 (2009).","journal-title":"Am J Kidney Dis"},{"key":"BFsrep32103_CR21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"Catena, C. et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50, 911\u2013918 (2007).","journal-title":"Hypertension"},{"key":"BFsrep32103_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcma.2014.11.005","volume":"78","author":"CE Chiang","year":"2015","unstructured":"Chiang, C. E. et al. 2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc 78, 1\u201347 (2015).","journal-title":"J Chin Med Assoc"},{"key":"BFsrep32103_CR23","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1210\/jc.2011-1135","volume":"96","author":"VC Wu","year":"2011","unstructured":"Wu, V. C. et al. Endothelial Progenitor Cells in Primary Aldosteronism: A Biomarker of Severity for Aldosterone Vasculopathy and Prognosis. J Clin Endocrinol Metab 96, 3175\u20133183 (2011).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep32103_CR24","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1038\/srep11396","volume":"5","author":"VC Wu","year":"2015","unstructured":"Wu, V. C. et al. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. Scientific reports 5, 11396 (2015).","journal-title":"Scientific reports"},{"key":"BFsrep32103_CR25","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/sim.3278","volume":"27","author":"MJ Woo","year":"2008","unstructured":"Woo, M. J., Reiter, J. P. & Karr, A. F. Estimation of propensity scores using generalized additive models. Statistics in medicine 27, 3805\u20133816 (2008).","journal-title":"Statistics in medicine"},{"key":"BFsrep32103_CR26","first-page":"783","volume":"80","author":"KD Wu","year":"1995","unstructured":"Wu, K. D. et al. Zona fasciculata-like cells determine the response of plasma aldosterone to metoclopramide and aldosterone synthase messenger ribonucleic acid level in aldosterone-producing adenoma. J Clin Endocrinol Metab 80, 783\u2013789 (1995).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep32103_CR27","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G Guder","year":"2007","unstructured":"Guder, G. et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115, 1754\u20131761 (2007).","journal-title":"Circulation"},{"key":"BFsrep32103_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1507\/endocrj.EJ13-0353","volume":"61","author":"Y Miyake","year":"2013","unstructured":"Miyake, Y. et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocrine journal 61, 35\u201340 (2013).","journal-title":"Endocrine journal"},{"key":"BFsrep32103_CR29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.surg.2010.09.012","volume":"148","author":"B Reimel","year":"2010","unstructured":"Reimel, B. et al. The management of aldosterone-producing adrenal adenomas\u2013does adrenalectomy increase costs? Surgery 148, 1178\u20131185; discussion 1185 (2010).","journal-title":"Surgery"},{"key":"BFsrep32103_CR30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"Rossi, G. P. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 62, 62\u201369 (2013).","journal-title":"Hypertension"},{"key":"BFsrep32103_CR31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/1470320314549220","volume":"16","author":"T Indra","year":"2015","unstructured":"Indra, T. et al. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. J Renin Angiotensin Aldosterone Syst 16, 1109\u20131117 (2015).","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFsrep32103_CR32","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/ndt\/gfs587","volume":"28","author":"Y Ori","year":"2013","unstructured":"Ori, Y. et al. Regression of left ventricular hypertrophy in patients with primary aldosteronism\/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 28, 1787\u20131793 (2013).","journal-title":"Nephrol Dial Transplant"},{"key":"BFsrep32103_CR33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MED.0b013e328360c200","volume":"20","author":"JS Williams","year":"2013","unstructured":"Williams, J. S. Evolving research in nongenomic actions of aldosterone. Curr Opin Endocrinol Diabetes Obes 20, 198\u2013203 (2013).","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"BFsrep32103_CR34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","volume":"30","author":"JA Ezekowitz","year":"2009","unstructured":"Ezekowitz, J. A. & McAlister, F. A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. European heart journal 30, 469\u2013477 (2009).","journal-title":"European heart journal"},{"key":"BFsrep32103_CR35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/ajh.2008.243","volume":"21","author":"B Strauch","year":"2008","unstructured":"Strauch, B. et al. Adrenalectomy improves arterial stiffness in primary aldosteronism. Am J Hypertens 21, 1086\u20131092 (2008).","journal-title":"Am J Hypertens"},{"key":"BFsrep32103_CR36","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1210\/jc.2007-2055","volume":"93","author":"P Mulatero","year":"2008","unstructured":"Mulatero, P. et al. Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 93, 1366\u20131371 (2008).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep32103_CR37","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1097\/HJH.0b013e3283495cbb","volume":"29","author":"VC Wu","year":"2011","unstructured":"Wu, V. C. et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens 29, 1778\u20131786 (2011).","journal-title":"J Hypertens"},{"key":"BFsrep32103_CR38","doi-asserted-by":"crossref","first-page":"15297","DOI":"10.1038\/srep15297","volume":"5","author":"CH Wu","year":"2015","unstructured":"Wu, C. H. et al. Effect of Treatment on Body Fluid in Patients with Unilateral Aldosterone Producing Adenoma: Adrenalectomy versus Spironolactone. Scientific reports 5, 15297 (2015).","journal-title":"Scientific reports"},{"key":"BFsrep32103_CR39","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1161\/HYPERTENSIONAHA.108.111369","volume":"51","author":"GP Rossi","year":"2008","unstructured":"Rossi, G. P. et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 51, 1366\u20131371 (2008).","journal-title":"Hypertension"},{"key":"BFsrep32103_CR40","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/HJH.0b013e328360ddf6","volume":"31","author":"X Sang","year":"2013","unstructured":"Sang, X. et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens 31, 1465\u20131471; discussion 1471\u20131462 (2013).","journal-title":"J Hypertens"},{"key":"BFsrep32103_CR41","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","volume":"371","author":"S Douma","year":"2008","unstructured":"Douma, S. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371, 1921\u20131926 (2008).","journal-title":"Lancet"},{"key":"BFsrep32103_CR42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2013.785234","volume":"45","author":"CT Chao","year":"2013","unstructured":"Chao, C. T. et al. Diagnosis and management of primary aldosteronism: an updated review. Annals of medicine 45, 375\u2013383 (2013).","journal-title":"Annals of medicine"},{"key":"BFsrep32103_CR43","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","volume":"340","author":"LE Levesque","year":"2010","unstructured":"Levesque, L. E., Hanley, J. A., Kezouh, A. & Suissa, S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340, b5087 (2010).","journal-title":"BMJ"},{"key":"BFsrep32103_CR44","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","volume":"342","author":"J Concato","year":"2000","unstructured":"Concato, J., Shah, N. & Horwitz, R. I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342, 1887\u20131892 (2000).","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1038\/srep45249","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32103","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:58:25Z","timestamp":1672898305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,30]]}},"alternative-id":["BFsrep32103"],"URL":"https:\/\/doi.org\/10.1038\/srep32103","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,2]]},"assertion":[{"value":"16 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32103"}}